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1. Introduction 
The gastrointestinal tract has various functions including digestion, the production of 
hormones with local and systemic effects, a major role in immunological function, and 
acting as a barrier against antigens within its lumen. The intestinal microflora is an 
ecosystem which harbours over 400 bacterial species, predominantly anaerobes which 
outnumber facultative anaerobes. Most flora is present in the large bowel, mainly in the 
lumen and attached to the mucosa, but they do not normally penetrate the bowel wall. 
Intestinal bacteria form an important part of the enterohepatic circulation. Metabolites 
conjugated in the liver (including drugs and endogenous compounds) are excreted in bile to 
be deconjugated by bacterial enzymes in the intestine, so that they can then be absorbed 
across the intestine into the portal circulation and returned to the liver. Antibiotics that alter 
the intestinal flora can change the fecal excretion and the serum levels of these metabolites. 
Bacterial flora also increase fiber digestion and are believed to decrease the risk of 
gastrointestinal infections by interfering with gut pathogens. Our intestine harbours low 
concentrations of potentially pathogenic organisms (such as Clostridium difficile). Antibiotics 
that alter the normal intestinal flora can increase the risk of infection by exogenous 
pathogens or through the overgrowth of endogenous pathogens, like Clostridium difficile. If 
the bowel wall is damaged by trauma, burns or inflammation, intestinal bacteria may escape 
into the peritoneum to cause peritonitis and / or abscesses.[1] 
Gastrointestinal dysfunction or gut failure frequently occurs in seriously ill patients and is 
responsible for bacterial translocation. This may in turn cause sepsis, with the initiation of a 
systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome 
(MODS), and / or death.[2] Gut dysfunction is also present in other conditions, including 
inflammatory bowel disease, Clostridium difficile infection, and liver cirrhosis. In this chapter, 
we investigate common conditions affecting the liver and the gut and their relation to sepsis, 
as well as investigating the role of gut decontamination and probiotics in stabilising the  
gut flora. 
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2. Sepsis in liver cirrhosis 
Liver cirrhosis occurs in response to chronic liver injury and involves the development of 
regenerative nodules surrounded by fibrous bands in the liver parenchyma. This in turn 
causes distortion of the hepatic vasculature, leading to portal hypertension and end stage 
liver disease. Cirrhosis leads to shunting of portal and arterial blood into the hepatic central 
veins, thus compromising the exchange between hepatic sinusoids and hepatocytes. 
Cirrhosis causes an impaired hepatocyte activity, portal hypertension and an increased risk 
of hepatocellular carcinoma. Hepatic vascular alterations and portal hypertension will in 
turn cause splanchnic vasodilatation, vasoconstriction and decreased renal perfusion, water 
and salt retention and an increased cardiac output.[3] 
The estimated prevalence of cirrhosis in the United States is 0.15% [4], though this may be 
an underestimate due to the high prevalence of undiagnosed cirrhosis in hepatitis C and 
Non-Alcoholic Steatohepatitis (NASH). Similar numbers have been reported from Europe, 
and numbers are even higher in most Asian and African countries where chronic viral 
hepatitis B or C are frequent. Since compensated cirrhosis is frequently not detected until 
routine investigations are performed, a reasonable estimate is that up to 1% of the world 
population may have histological cirrhosis. Alcoholic liver disease and hepatitis C are the 
commonest causes of cirrhosis in the Western world, while hepatitis B is the most common 
cause in most parts of Asia and sub-Saharan Africa. Cryptogenic cirrhosis (cirrhosis without 
a recognised cause) is nowadays rarely diagnosed, particularly after the identification of the 
hepatitis C virus in the late 1980s and with the identification of nonalcoholic steatohepatitis 
in obese and diabetic subjects.[3] 
Bacteraemic infections are more frequent in patients with hepatic cirrhosis. 9% of the overall 
number of bacteraemic episodes in newly-admitted patients occur in cirrhotic patients [5] 
and 46% of cirrhotic patients have bacterial infections on admission.[6] Advanced cirrhotics 
are more likely to have the systemic inflammatory response syndrome. This syndrome 
correlates with bacterial infection at admission and has been shown to be associated with a 
poor outcome.[7] Animal studies have identified the gut as the principal source of infection 
in liver cirrhosis, mainly through bacterial overgrowth and translocation in the small bowel. 
However, cultures of small intestinal mucosal bacteria in cirrhotic patients have shown that 
these microbiota are qualitatively and quantitatively normal. This has shifted attention 
towards factors that decrease gut integrity, or alter the removal of translocating bacteria as 
causative factors of bacteraemia in cirrhosis.[8] It is hypothesized that in cirrhosis the 
intestine is more permeable, allowing bacteria easy access into the circulation through the 
gut mucosa with consequent macrophage activation. This permeability is further increased 
in patients with portal hypertension. Serum levels of interleukin-6 and soluble receptors of 
tumor necrosis factor were shown to be significantly higher in HIV-HCV co-infected and 
HCV mono-infected patients with decompensated cirrhosis when compared with those with 
compensated liver disease.[9] This susceptibility was also demonstrated in non-alcoholic 
steatohepatitis.[10] In patients with cirrhosis and severe sepsis, high production of pro-
inflammatory cytokines seems to cause a deterioration in liver function and predisposes to 
the development of shock, renal failure, acute lung injury or acute respiratory distress 
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syndrome, coagulopathy, or hepatic encephalopathy. Variants of the NOD2 gene (100fs and 
G908R) appear to increase bacterial translocation in cirrhotics and have been associated with 
spontaneous bacterial peritonitis in a recent study.[11] There is an increased risk for culture-
positive spontaneous bacterial peritonitis and infected ascites in cirrhotic patients with these 
variants.[11] 
The second theory is that patients with chronic liver disease tend to have impaired bacterial 
clearance. This was demonstrated when quantitative real-time polymerase chain reaction 
(PCR) using primers that amplify all known bacteria was used to measure bacteraemia 
following tooth-brushing. The investigators showed greater than 75% bacteraemia following 
tooth-brushing, but while control subjects were able to clear this bacteraemia, subjects with 
cirrhosis had prolonged bacteraemia, suggesting that cirrhotic patients may be more 
susceptible to sepsis because of ineffective bacterial clearance.[12]  
The mortality rate of patients with liver cirrhosis is significantly higher than that of patients 
with other diseases when they develop bacteraemia, and underlying cirrhosis is an 
independent risk factor for mortality in bacteraemic patients. In-hospital mortality rate in 
patients with liver cirrhosis and sepsis was shown to be up to 30% [13-16], with another 30% 
dying by 1 year.[16] Factors which are significantly associated with in-hospital mortality are 
the presence of more than 1 site of infection, pneumonia, Child’s C status and a model for 
end-stage liver disease (MELD) score of 17 or more. In-hospital mortality rate increases as 
the number of factors increases (7% with one factor, 21% with two factors, 87% with three 
factors and 100% with four factors).[13] The initial CRP level does not predict mortality 
secondary to sepsis in liver cirrhosis patients. However, serial CRP measurements during 
the first week of antimicrobial therapy may be a useful prognostic factor for mortality in 
cirrhotic patients.[14] In a nationwide Korean surveillance study comparing bacteraemia in 
patients with liver cirrhosis with bacteraemia in patients with other liver diseases, patients 
with cirrhosis were shown to be more likely to have Klebsiella pneumonia bacteraemia (20.1% 
vs 14.3%, P=0.018) but less likely to have coagulase-negative staphylococcal bacteraemia 
(5.1% vs 10.4%, P=0.028).[14] 
One of the sequelae of cirrhosis is the development of ascites. Patients with ascites have an 
increased risk of developing spontaneous bacterial peritonitis (SBP) with a prevalence of 10-
30%. Even with early diagnosis and management of spontaneous bacterial peritonitis, 
mortality is still 31% at 1 month and 66% at 12 months.[16] SBP is a very common bacterial 
infection in patients with cirrhosis and ascites.[17] Bacterial translocation is believed to be 
responsible for the first step in the pathogenesis of spontaneous bacterial peritonitis. 
Translocation is only possible because of the concurrent failure of the defensive mechanisms 
in cirrhosis. Research has confirmed an increased bacterial translocation in cirrhotic rats. 
There is also pronounced impairment of gastrointestinal tract motility in cirrhosis. A 
disturbance of the gut microflora thus occurs and this, in association with changes in the 
permeability of the gastrointestinal tract, causes the passage of microorganisms and 
endotoxins to the mesenteric lymph nodes.[18] The diagnosis of SBP is based on diagnostic 
paracentesis. Half the episodes of SBP are present on hospital admission while the rest are 
acquired during hospitalization.[19] SBP may present with peritonitic signs (abdominal 
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pain, tenderness, vomiting, ileus), fever, elevated white cell counts, tachycardia, 
hypotension, worsening of liver function, hepatic encephalopathy, renal failure and 
gastrointestinal bleeding. However, cirrhotic patients with SBP may be completely 
asymptomatic. Empirical antibiotics should be started immediately following the diagnosis 
of SBP. The first line antibiotic treatment in SBP are the third generation cephalosporins, as 
the commonest causative organisms are Gram-negative aerobic bacteria.[20] Other options 
include co-amoxiclav, ciprofloxacin and ofloxacin (though quinolones should not be used in 
patients who are using these antibiotics for SBP prophylaxis, in areas where there is a high 
prevalence of quinolone resistance or in nosocomial SBP). Antibiotics are effective in the 
management of SBP in approximately 90% of patients. Failure of antibiotic therapy usually 
occurs due to bacterial resistance or because of missed secondary bacterial peritonitis. If 
secondary bacterial peritonitis has been excluded, the antibiotic needs to be changed 
according to the culture and sensitivity results of the isolated organisms, or else modified to 
an alternative empiric broad spectrum agent.[21] 
Hepato-renal syndrome (HRS) refers to the rapid deterioration of renal function in patients 
with liver cirrhosis. It occurs in approximately 30% of patients with SBP treated with 
antibiotics alone and is associated with a very poor survival. Albumin administration (1.5 
g/kg at diagnosis and 1 g/kg on day 3) decreases the frequency and mortality of HRS in 
cirrhotic patients with SBP. For this reason, the European Association for the Study of the 
Liver (EASL) guidelines recommend that all cirrhotic patients who develop SBP should be 
treated with intravenous albumin and empirical antibiotics.[21] 
In patients at high risk of developing SBP, antibiotic prophylaxis is recommended.[21] Since 
it is hypothesised that SBP occurs following the translocation of enteric Gram negative 
bacteria from the gut to the circulation, the ideal prophylactic antibiotic needs to be effective 
at decreasing the amounts of these organisms in the gut without altering the protective 
anaerobic flora. The use of prophylactic antibiotics should be strictly restricted to patients at 
high risk of SBP to decrease the risk of developing resistance. These high-risk patient 
populations include cirrhotics with acute gastrointestinal hemorrhage, those with low total 
protein content in ascitic fluid and no prior history of SBP (primary prophylaxis) and 
patients with a previous history of SBP (secondary prophylaxis). In such high-risk patients, 
antibiotics should be started immediately (i.e. following upper gastrointestinal bleed, after a 
first episode of SBP or upon finding low total protein) and are recommended life-long, or 
until liver transplant is performed. 
Bacterial infection is a major problem in cirrhotic patients with acute gastrointestinal 
hemorrhage, occurring in 25 - 65% of these patients.[22] Bacteraemia in patients with 
variceal hemorrhage is associated with a decreased ability to control bleeding [23], an 
increased rebleeding rate, and increased hospital mortality.[24] Antibiotic prophylaxis has 
been shown to prevent infection in patients with gastrointestinal bleeding and decrease the 
rate of rebleeding. A meta-analysis of five studies performed in patients with 
gastrointestinal bleeding [25-29] has shown that antibiotic prophylaxis significantly 
decreased both the incidence of severe infections (SBP and/or sepsis) and mortality. The 
preferred antibiotic for SBP prophylaxis is norfloxacin (400 mg/12 h orally for 7 days) which 
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provides selective intestinal decontamination. Norfloxacin is a quinolone antibiotic with 
antibacterial activity against Gram-negative bacteria but not against Gram-positive cocci or 
anaerobic bacteria. However, in view of the increasing incidence of quinolone-resistant 
bacteraemia [30-32], and because a substantial number of infections in patients with 
gastrointestinal hemorrhage are caused by Gram-positive bacteria, ceftriaxone has been 
studied as a prophylactic agent in cirrhotics with gastrointestinal bleeding. A study 
comparing oral norfloxacin with intravenous ceftriaxone for the prophylaxis of bacterial 
infection in cirrhotic patients with gastrointestinal bleeding showed that ceftriaxone was 
more effective than norfloxacin in the prevention of infections.[33] The main disadvantage 
with ceftriaxone is that it must be given intravenously and is therefore limited to hospital 
use. Cirrhotic patients with low protein concentrations (<10 g/L) in their ascitic fluid and/or 
high serum bilirubin levels are at an increased risk of developing SBP.[34] Studies have 
shown that norfloxacin (400 mg/day) is effective as a prophylactic agent against SBP and 
improves survival in patients with low total protein in their ascitic fluid.[35-37] Following 
an episode of SBP, the cumulative recurrence rate at 1 year is approximately 70% [38], with a 
1-year survival probability of 30–50% and a 2-year survival probability of 25–30%. 
Prophylactic norfloxacin (400 mg/day, orally) reduces the risk of recurrent SBP. Other 
antibiotics which may be used in SBP prophylaxis after the first episode of SBP include 
ciprofloxacin (750 mg once weekly, orally) or co-trimoxazole (800 mg sulfamethoxazole and 
160 mg trimethoprim daily orally), but the evidence with these antibiotics is not as strong as 
with norfloxacin. The EASL guidelines also recommend that patients recovering from SBP 
should be considered for liver transplantation.[21] The American Association for the Study 
of the Liver and the British Society of Gastroenterology guidelines [39,40] have similar 
recommendations for the management of spontaneous bacterial peritonitis and its 
prophylaxis. 
Terlipressin is a vasoactive agent used in patients with septic shock and which has a 
selective affinity to vascular V1 receptors. It is an effective pressor agent in patients with 
catecholamine-unresponsive septic shock. Additional studies are needed to identify the best 
time to start terlipressin, the efficacy and dosages of continuous infusion versus bolus 
administration as well as the safety and efficacy of this compound in comparison with other 
vasoactive drugs.[41,42] 
3. Acute cholangitis 
Acute cholangitis and biliary sepsis are severe infectious diseases, frequently observed in 
patients with obstructive jaundice. The presence of bacteria in the biliary tract increases in 
the presence of biliary obstruction, particularly in the presence of foreign bodies like stones, 
but also in the presence of malignant obstruction secondary to pancreatic head carcinoma or 
cholangiocarcinoma. Reflux of bacteria from the biliary tract to the systemic circulation is 
believed to be the primary etiologic factor in bacteraemia and the development of sepsis in 
cholangitis. Biliary tract obstruction is the initiating factor in the pathogenesis of acute 
cholangitis causing elevated intraluminal pressures, and subsequent infection of the 
normally sterile bile. Bacteria may infect bile retrogradely from the gut (through the 
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ascending route), through the haematogenous route or via lymphatics. The presence of 
bacteria in the biliary tract (bactibilia) increases rapidly with the development of biliary 
obstruction, particularly in the presence of foreign bodies like stones. Biliary obstruction 
causes local and systemic changes in the host defenses. There is decreased bile passage into 
the small bowel and decreased secretory IgA from the gastrointestinal tract. This promotes 
changes in the gut bacterial flora which in turn cause loss of mucosal integrity, decreased 
endotoxin inactivation and bacterial overgrowth. These changes cause portal bacteremia, 
endotoxemia and increased translocation of endotoxins to the liver, resulting in sepsis and 
also decreasing the hepatic Kupffer cell function in these patients. In view of these 
pathophysiological changes, early biliary decompression is necessary to restore normal 
function of the Kupffer cells in the liver and thus prevent functional alterations in the liver 
because of chronic, long-standing obstruction and cholestasis. Early biliary decompression 
also decreases postoperative morbidity and mortality.[43] The increased expression of 
triggering receptor expressed on myeloid cells (TREM-1) in the peripheral blood 
mononuclear cells of sepsis patients with acute cholangitis suggests an important role of 
TREM-1 in the development of acute cholangitis.[44, 45]  
The predominant pathogens cultured from bile specimens in patients with obstructive 
jaundice (samples obtained at endoscopic retrograde cholangiopancreatography (ERCP) or 
percutaneous transhepatic biliary drainage) were gram-negative bacteria (68%) followed by 
gram-positive bacteria (26%), anaerobes (3%) and Candida (3%).[46] The predominant 
gram-negative pathogens were Eschericia coli, Acinetobacter baumani complex, Klebsiella 
pneumonia and Enterobacter cloacae. The most effective antibiotics against the gram-negative 
bacteria were shown to be imipenem (susceptibility: 97.9%), cefoperazone/sulbactam 
(89.4%), piperacillin/tazobactam (85.1%) and cefepime(85.1%).[46] Another study on patients 
with acute cholangitis [47] confirmed that gram-negative organisms are responsible for most 
bacteraemias (95%), with the commonest ones being Eschericia coli (62%), and Klebsiella 
pneumonia (26%). This study found that bacteraemias caused by biliary tract infection 
represented 5.5% of all causes of bacteraemias. Thirty-day mortality among these patients 
was 14% with 57% of these patients dying secondary to septic shock.[47] The management 
of ascending cholangitis involves the use of appropriate antibiotics and drainage of the 
biliary tract. Treatment should target Enterobacteriaceae with a cephalosporin, and if the 
patient becomes hypotensive, an aminoglycoside effective against ESBL-producing E. coli or 
Klebsiella pneumonia should also be administered. Biliary drainage, by ERCP or percutaneous 
transhepatic cholangiography, is frequently needed for adequate biliary decompression.[47] 
Patients undergoing ERCP tend to be at high risk of sepsis because of the underlying biliary 
obstruction which predisposes to cholangitis and because of the invasive nature of the 
procedure. The use of prophylactic antibiotics before ERCP is therefore recommended by all 
major international gastroenterological societies, especially in the presence of an obstructed 
biliary system.[48-50] The use of prophylactic antibiotics attempts to decrease or eliminate 
the incidence of cholangitis, sepsis and pancreatitis after the procedure.[48] During ERCP, 
bacteraemia is believed to occur because of the injection of contrast and the iatrogenic 
introduction of foreign substances in the bile of patients who already have underlying 
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pathologies such as biliary obstruction or pancreatic pseudocysts. Bacteraemia during ERCP 
is relatively uncommon in patients who do not have evidence of biliary or pancreatic ductal 
obstruction.[49] Bacteraemia is however well recognised during ERCP for biliary 
obstruction with pancreatic or biliary infection occurring following 0.4–0.8% of endoscopic 
biliary procedures. These episodes must always be taken seriously because of the associated 
8–20% mortality risk.[50] Biliary dilatation, the insertion of biliary stents, prolonged 
procedure time and hilar cholangiocarcinoma have been shown to give an increased risk of 
post-ERCP cholangitis.[51] The British Society of Gastroenterology and the American 
Society of Gastrointestinal Endoscopy have similar recommendations on the prophylactic 
use of antibiotics for ERCP.[52,53] Patients with ongoing cholangitis who will be needing 
therapeutic endoscopic intervention should always be on appropriate antimicrobial therapy 
upon admission to hospital. Additional pre-ERCP antimicrobial prophylaxis is not normally 
recommended for those who are already taking antibiotics therapeutically for cholangitis. 
Routine prophylaxis for ERCP is not usually necessary, unless it is not possible to 
adequately decompress the biliary system during the procedure, in which case a full 
antibiotic course is indicated until adequate drainage can be achieved. Indications for 
routine antibiotic prophylaxis during ERCP include specific biliary disorders, such as 
primary sclerosing cholangitis or hilar cholangiocarcinoma (where complete biliary 
drainage will be difficult or impossible to achieve during one procedure), patients with a 
history of liver transplantation, patients with pancreatic pseudocysts, patients with severe 
neutropenia and / or advanced haematological malignancy. When antibiotic prophylaxis for 
ERCP is given, oral ciprofloxacin or intravenous gentamicin is usually recommended.  
4. Inflammatory bowel disease and sepsis 
Bacteria play an important role in the pathogenesis of inflammatory bowel disease (IBD), its 
complications and its symptoms. In IBD, antibiotics can decrease tissue invasion and 
eliminate aggressive bacterial species. Antibiotics are also used in IBD to treat infective 
complications and for altering bacterial flora, which may result in specific anti-inflammatory 
effects. The antibiotics which are used most frequently in IBD are metronidazole and 
ciprofloxacin, which may be effective in Crohn’s colitis and ileocolitis, perianal disease and 
pouchitis.[54]  
The pathophysiology of both Crohn’s disease (CD) and ulcerative colitis (UC) involves 
dysfunction of the intestinal barrier, which then causes leak flux diarrhoea and the 
facilitated uptake of noxious antigens into the systemic circulation. Barrier dysfunction in 
IBD involves a reduction in epithelial horizontal tight junctions (TJ) and an abnormal TJ 
protein expression. An increased incidence and frequency of apoptosis as well as erosions 
and ulcerations in the gastrointestinal mucosa can add to the leakiness of the gut. The 
dysfunction of the intestinal barrier occurs because of the increased expression of pro-
inflammatory cytokines like Tumor Necrosis Factor alpha, Interferon gamma, Interleukin 
1β, and Interleukin 13 in the chronically inflamed intestine. Chronic inflammation in IBD is 
believed to result from genetic polymorphisms which cause an inadequate immune 
response as well as changes in the intestinal microbiota. Probiotics may offer some benefit in 
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IBD by stabilising the barrier function through TJ protein expression and distribution.[55] In 
CD, an increased presence of Campylobacter concisus and Escherichia coli as well as a 
substantial decrease in the amount of the anti-inflammatory commensal Faecalibacterium 
prausnitzii has been reported, while it has been suggested that Fusobacterium varium can 
promote the development of UC.[56-60] Cultures of Mycobacterium avium subspecies 
paratuberculosis (MAP) in the peripheral blood of CD patients and controls have revealed 
that MAP is commoner in CD patients, thus suggesting that MAP may have a role in the 
aetiology of CD.[61] Smokers with CD have also been shown to have luminal microbiota 
that consist of significantly higher bacteroides (38.4%) than non-smokers (28.1%).[62] While 
these microbiota frequently do not cause sepsis, sepsis is significantly commoner in IBD, 
both in immunosuppressed patients and in patients who are newly diagnosed and not on 
immunosuppressive therapy.[63-64] An increased incidence of bacterial endocarditis in both 
UC and CD has also been reported.[65] Rifaximin appears to be a promising antibiotic in 
inducing remission of CD (69% in open studies and significantly better than placebo in 
double blind trials) and UC (76% in open studies and significantly better than placebo in 
controlled studies). It may also have a role in remission of UC and pouchitis.[56] 
Genetic polymorphisms play a major role in the aetiology of inflammatory bowel disease 
(IBD). Major advances in the aetiology of CD came from the discovery of polymorphisms in 
the NOD2 (nucleotide-binding oligomerization domain containing 2), autophagy-related 
susceptibility genes ATG16L1 (Autophagy-related 16-like gene) and IRGM (Immunity-
Related Guanosine Triphosphate) in patients. The identification of the presence of adherent-
invasive E. coli (AIEC) which are able to resist killing by macrophages on the ileal mucosa 
was another step forward in understanding the aetiology of Crohn’s disease.[66] Mutations 
in NOD2 gene which cause loss of function of NOD proteins are strongly associated with 
ileal Crohn’s disease. NOD2 is one of the genes controlling microbiota in the intestine, with 
studies showing loss of regulation of microflora in the terminal ileum of NOD2-deficient 
mice. Paneth cells, which regulate ileal microbiota by the production of anti-microbial 
compounds, show an elevated expression of the NOD2 gene, and therefore ileal intestinal 
epithelial cells which lack NOD2 are unable to destroy bacteria effectively. NOD2 mutations 
in CD therefore appear to increase disease susceptibility by disrupting the interaction 
between mucosal immunity and the ileal microflora.[67] NOD2 appears to activate pro-
inflammatory signalling cascades once bacterial muramyl dipeptide has been sensed by the 
epithelial cells. It also seems to be involved in antiviral and anti-parasitic defence programs.  
On the other hand, ATG16L1 is a protein necessary for autophagosome formation once 
bacterial or parasitic components are introduced into cells. Gene polymorphisms resulting 
in dysregulated immune responses to invasive micro-organisms, including those in the 
NOD2 and ATG16L1 genes, facilitate microbial replication and loss of the functional 
integrity of the epithelial barrier with an increase in permeability. The access to sub-
epithelial tissues by the invasive micro-organisms may cause local chronic inflammation 
and microbial dissemination which may result in systemic inflammatory responses. The 
associated impaired response of myeloid cells to this microbial insult also increases the risk 
of chronic, low grade infection and inflammation.  
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5. Pouchitis 
Restorative proctocolectomy with ileal-pouch anal anastomosis is the operation of choice for 
UC patients requiring surgery. It is also used for patients with familial adenomatous 
polyposis (FAP). Chronic pouchitis is an important long-term complication following ileal-
pouch anal anstomosis, accounting for 10% of pouch failures and occurring in 50% of 
patients after pouch formation for UC. It is however rarely seen in FAP, suggesting that 
pouchitis tends to occur because of the inflammatory process occurring in UC. Antibiotics 
are effective in reducing the symptoms of pouchitis, implicating bacteria in its 
development.[68] Studies have revealed that patients with pouchitis have different bacterial 
families (Peptostreptococcaceae, Clostridiaceae) from patients with normal pouches 
(Ruminococcaceae, Bifidobacteriaceae).[69] Bacterial species in pouchitis are important 
because of the benefit that some probiotics have been shown to offer to these patients, as 
indicated in the next section.  
6. Immunosuppressants in IBD 
The increased risk of sepsis and bacteraemia in IBD patients has already been established. 
The treatment of IBD frequently involves the use of potent immunosuppressing agents 
including steroids, azathioprine, 6-mercaptopurine, methotrexate and biological drugs 
including infliximab and adalimumab. Potential complications with the use of these agents 
in IBD patients include sepsis. A recent meta-analysis which reviewed early post-operative 
infectious complications in UC patients undergoing colectomy showed no significant 
difference in the rate of infectious complications between patients who were treated with 
infliximab and those who were not.[70] In an analysis of serious infections (defined as 
infections requiring hospital admission) among 489 IBD patients receiving anti-TNFα 
therapy across Australia and New Zealand, only 14 (2.2%) serious infections were reported. 
These infections included 3 cases of Varicella Zoster, 2 cases of Pneumocystis jiroveci 
pneumonia, 2 flu-like illnesses, two cases of Staphylococcus aureus bacteraemia and five other 
bacterial infections.[71] Another single-centre analysis on the safety of infliximab in CD, 
revealed that in 297 patients on infliximab there was a 2.7% rate of serious infection, with 
0.33% resulting in fatal sepsis.[72] Case reports of sepsis in patients treated with biological 
therapy are also numerous.[73-77] Active sepsis is an absolute contraindication for anti-TNF 
therapy use, as this risks overwhelming sepsis. Reactivation or development of tuberculosis 
has been reported in 24/100,000 patients with rheumatoid arthritis on anti-TNF therapy, 
compared with 6/100,000 not receiving such treatment.[78,79] 
Reports of severe sepsis in patients with IBD while taking Azathioprine have also been 
described.[80,81] Azathioprine and 6-mercaptopurine are used in patients with moderate to 
severe CD or UC. Azathioprine has a complex, heterogeneous thiopurine methyltransferase 
(TPMT) metabolism which may affect required dosages and may increase the risk for 
adverse events. Routine TPMT activity testing before starting Azathioprine may decrease 
the risk of early leukopenia and avoid potentially life-threatening myelotoxicity.[82] The 
risk of severe sepsis increases further if combination immunosuppressants (such as 
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combinations of azathioprine and anti-TNFα agents) are used.[83] The TREAT registry 
showed that while unadjusted analysis indicated that Infliximab is associated with an 
increased risk of infection, multivariate logistic regression analysis suggested that Infliximab 
was not an independent predictor of serious infections and the increased risk was associated 
with disease severity and concomitant prednisone use.[84] The REACH study, evaluating 
the efficacy of Infliximab in children with moderate to severe CD refractory to 
immunomodulatory treatment, reported serious infections as the major adverse events with 
their frequency being higher with shorter treatment intervals. The combination of 
immunosuppressive medications appears to increase the risk of opportunistic infections.[85]  
7. Streptococcus gallolyticus and colorectal tumours 
Streptococcus gallolyticus, previously called S.bovis biotype I (Table 1) is a gram positive 
bacterium found in the colon of 10% of healthy individuals. It is an opportunistic pathogen 
as it can cause bacteraemia and endocarditis, especially in the presence of colorectal cancer 
(CRC). In the International Collaboration on Endocarditis Prospective Cohort Study, S. 
gallolyticus accounted for a very significant 12.5% of the cases of infective endocarditis in 
patients over 65 and 5.4% in those 18-65 years of age.[86] The association between S.bovis 
bacteraemia and colonic neoplasia was first reported in the literature in 1951 by McCoy and 
Mason.[87] In a recent meta-analysis [88], among the S.bovis-infected patients who 
underwent colonoscopy, 60% of patients had underlying adenomas or carcinomas. One 
hypothesis on the association between CRC and S. gallolyticus suggests that colorectal 
malignancy specifically allows for colonisation and translocation of the bacterium through 
the altered mucosa. An alternative theory proposes that the organism itself promotes 
carcinogenesis by interacting with the colonic mucosa. Several studies comparing faecal 
carriage of S. gallolyticus in patients with colorectal cancer or adenomatous polyps with 
normal controls failed to show a significant difference.[87,89,90] However, studies on 
patients with proven S. gallolyticus bacteraemia consistently showed that 25 to 80% of 
patients with the infection had colorectal tumours. Similarly, 18 to 62% of patients with S. 
gallolyticus endocarditis have been diagnosed with colonic neoplasia.[91] 
 
Old nomenclature Later nomenclature Recent nomenclature 
S. bovis biotype I S. gallolyticus S. gallolyticus subsp. gallolyticus 
S. bovis biotype II/1 
S. infantarius 
S. infantarius subsp. coli 
S. infantarius subsp. infantarius 
S. lutetiensis 
S. bovis biotype II/2 
S. pasteurianus 
S. macedonicus 
S. gallolyticus subsp. pasteurianus 
S. gallolyticus subsp. macedonicus 
Table 1. Nomenclature of Streptococcus gallolyticus 
7.1. Virulence factors and possible carcinogenic effect of S. gallolyticus 
Boleij et al [92] reconstructed the route of infection in vitro on a continuous cell line of 
heterogenous human epithelial colorectal adenocarcinoma cells that can be synthesized into 
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a monolayer and which simulate the intestinal epithelium. Cellular immune responses upon 
infection and bacterial biofilm formation were analysed. The S. gallolyticus strains have a 
relatively low adhesiveness and are unable to internalise epithelial cells. However, they are 
able to cross a differentiated epithelium without inducing an interleukin 8 or 1β response 
within the epithelium. The organism has a particular ability to form biofilms on collagen-
rich surfaces (representing heart valves in vivo). The authors concluded that S. gallolyticus 
has the ability to evade the innate immune system of the intestinal epithelium and the 
potential to form vegetations over collagen-rich surfaces as is observed in vivo.  
7.2. Association with liver disease and extracolonic malignancy 
S. gallolyticus has also been associated with chronic liver disease. Tripodi et al prospectively 
studied 199 patients with infective endocarditis and found that 30 of these were attributable 
to S. bovis biotype I (S. gallolyticus).[93] 56.7% of these patients had advanced liver disease, 
compared with only 15.3% of patients with non-S.bovis endocarditis, while colonic 
adenomas were present in 46.7% of cirrhotics. Alazmi and his team [94] retrospectively 
analysed microbiology data from 46 patients (38 adult and 8 paediatric) with proven 
S.gallolyticus bacteraemia and found that 19% had end-stage liver disease while colonic 
neoplasia was found in 6 of 10 adult patients in whom colonoscopy was performed. 7 of the 
adult patients had AIDS while no significant association with gastrointestinal disease was 
found in the paediatric population. An association between S. gallolyticus and extracolonic 
malignancy is less well established. Gold et al [95] report a series of 45 patients with 
documented S. gallolyticus bacteraemia. Eight of these patients had malignant lesions arising 
within the gastrointestinal tract, and 5 patients had extraintestinal malignancies. Vergara-
López et al looked at 93 patients with S. gallolyticus bacteraemia [96] and found that 25% of 
individuals had a colonic neoplasm while 14 patients (15%) were diagnosed with non-
colonic neoplasms including biliary and pancreatic (6.5%) and esophagogastric (3.2%) 
neoplasms. In view of these observations, the authors recommend that in the absence of 
colonic neoplasms clinicians should do a thorough investigation of the gut with gastroscopy 
and appropriate imaging of the hepatobiliary system.  
8. Conclusion 
A considerable body of evidence links colonic neoplasms with S.gallolyticus bacteraemia but 
many unanswered questions remain about this association. Evaluation of the colon by 
colonoscopy is essential in all cases of S. gallolyticus bacteraemia. In view of the high incidence 
of chronic liver disease and extracolonic neoplasms in some studies, formal evaluation of the 
liver may be warranted with or without cross sectional imaging of the abdomen. In the future, 
biomarkers for this organism may allow early diagnosis of colonic neoplasia. 
8.1. Selective decontamination of the digestive tract 
In critical illness, sepsis plays a major role in morbidity and mortality. Bacterial translocation 
from the gut is believed to occur following loss of the barrier function of the intestinal 
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mucosa. Selective decontamination of the digestive tract (SDD) involves the use of local and 
systemic antimicrobial agents to clear potentially pathogenic organisms from the 
gastrointestinal tract, especially Gram negative organisms, Staphylococcus aureus and yeasts, 
while avoiding agents that inhibit the anaerobic flora. Reduction of the Gram negative 
bacterial load would be followed by a decrease in sepsis and bacteraemia. However, in spite 
of the evidence in favour of SDD, it is still not in widespread use in intensive-care units 
(ICU).  
SDD involves the combination of orally administered non-absorbed antibiotic and 
antifungal agents with an intravenous broad spectrum antibiotic. A regimen that has been 
used in several major studies consists of orally administered amphotericin-B, tobramycin and 
colistin.[97,98] Along with the topical agents, intravenous cefotaxime is also given for the first 
four days of ICU stay. The systemic antibiotics should cover both community-acquired 
organisms and hospital-acquired organisms while having minimal influence on the normal 
bowel flora and good penetration to bronchial secretions, making cefotaxime an ideal 
candidate.[99] The enteral non-absorbable antibiotics are intended to prevent secondary 
endogenous infections but they fail to cover resistant organisms such as MRSA. Silvestri et al 
[100] have added oral vancomycin to Polymyxin E, tobramycin and amphotericin B in an 
attempt to decrease the incidence of MRSA ventilator-associated pneumonias (VAP). This 
combination was effective in reducing the incidence of VAP and secondary carriage of MRSA 
with no reported cases of vancomycin-resistant Enterococci or vancomycin-intermediate 
Staphylococcus aureus. In most randomised controlled trials, SDD has been compared to 
Selective Oropharyngeal Decontamination (SOD) and standard care. SOD involves local 
application of non-absorbable antibiotics restricted to the oropharynx, usually applied in the 
form of a gel. The topical antimicrobial combination for SOD is usually similar to the 
combination used in SDD. Studies have shown that both SDD and SOD are useful in 
preventing sepsis in critically ill patients but few studies have analysed the effect of their use 
on the prevalence of resistant organisms within ICUs. This remains an area that needs further 
study and is a major issue that precludes the widespread use of SDD.[101] 
8.2. The evidence on SDD 
Many randomised controlled trials (RCT) have been performed over the last decade 
studying the benefits and risks of SDD. An important recent RCT studied the effect of SDD 
and SOD on 28-day mortality in ICU patients.[97] 5939 patients in 13 different ICUs in the 
Netherlands were enrolled to receive either standard care, SDD or SOD. SDD included the 
application of topical tobramycin, colistin and amphotericin B to the oropharynx and 
stomach along with the intravenous administration of cefotaxime for the first four days of 
ICU stay. 28-day mortality was marginally reduced from 27.5% in patients treated with 
standard care to 26.6% and 26.9% in the SDD and SOD groups respectively. Another RCT 
looked at the role of oropharyngeal and intestinal colonisation with gram-negative bacteria 
as a source of ICU-acquired bacteraemia.[102] This trial randomised a total of 6778 ICU 
patients to receive SDD, SOD or standard care. The outcomes measured included the 
incidence densities (episodes per 1000 ICU patient days) of ICU-acquired gram-negative 
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bacteraemia and rectal colonisation with gram-negative bacteria. SOD gave a 33% reduction 
while SDD gave a 45% reduction in the incidence of Gram-ve bacteraemia.  
In another study [103], 107 patients with more than 20% burns and/or suspected inhalation 
injury were randomised to receive SDD or placebo and mortality rates and incidence of 
pneumonias were measured. A similar antibiotic regimen to the one used in [97] was used 
but topical polymixin E substituted colistin. Results showed an ICU mortality of 27.8% in 
the placebo arm compared to 9.4% in the SDD arm. Rates of pneumonia were 30.8 and 17.0 
per 1000 ventilator-days in the placebo and the SDD arms respectively. The authors also 
noted that MRSA infection was commoner in the SDD group amounting to 26.4% versus 
20% in the placebo group. Various other trials have been summed up by three major meta-
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Table 2. Meta-analysis on benefits of SDD in preventing sepsis. (BSI blood stream infection, RTI 
respiratory tract infection, SDD selective decontamination of the digestive tract, SOD selective 
oropharyngeal decontamination, G+ gram positive, G- gram negative, NNT numbers needed to treat, 
OR odds ratio) 
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8.3. Prevention of Ventilator-Associated Pneumonia (VAP)  
Pneumonia is a major cause of mortality in critically ill and ventilated patients. The 
incidence of VAP in different studies ranges between 7 and 40% while mortality ranges from 
25 to 50%.[107] In an important meta-analysis carried out by Liberati et al [104], 36 RCTs 
studying the effects of different combinations of SDD and SOD in ICU patients on the 
incidence of VAP were analysed. This showed that in trials comparing combined topical and 
systemic antibiotics to controls, there was a significant reduction in both VAP and mortality 
in the treated group. In trials comparing topical antibiotics to controls, a significant 
reduction in VAP (but not in total mortality) was shown.[108] Methicillin-Resistant 
Staphylococcus aureus (MRSA) is a common cause of VAP. In a study by Silvestri et al [106], 
oropharyngeal vancomycin was applied along with standard SDD using only enteral non-
absorbable antibiotics in a group of ventilated ICU patients. The rate of pneumonia due to 
MRSA was reduced in the vancomycin group when compared to controls who received only 
the topical SDD. Patients in this study were also investigated for the emergence of 
vancomycin-resistant Enterococci and vancomycin-intermediate S. aureus but these bacteria 
were not isolated. This suggests that the addition of topical glycopeptides to the SDD 
regimen may help reduce the rate of MRSA though further studies are needed before this 
approach can be recommended.  
8.4. Evidence supporting use in surgical patients 
Roos et al [109] studied the incidence of infections and anastomotic leakage 30 days 
following surgery in 289 patients receiving either topical SDD or placebo. Results show that 
19.6% of the SDD group had infectious complications when compared to 30.8% in the 
placebo group. Anastomotic leakage was also reduced in the SDD group (6.3% vs 15.1%). In 
spite of this, there was no significant difference in mortality or hospital stay between the two 
groups. Melsen et al [110] compared the benefits of SOD and SDD in surgical and medical 
ICU patients. 2762 surgical and 3165 non surgical patients were randomised to receive SDD, 
SOD or standard care. Compared with standard care, mortality was comparable in SDD 
treated surgical and non surgical patients though the duration of ventilation, ICU and 
hospital stay were significantly reduced in the surgical patients. SOD failed to reduce 
mortality when compared to standard treatment in the surgical cohort while providing a 
reduced mortality by 16.6% in non-surgical patients. Patients undergoing liver transplant 
are very vulnerable to infection during the early post-operative period, particularly with 
gram-negative organisms. SDD has been studied in these patients in several RCTs [111-113] 
and meta-analyses [114]. The results have been conflicting and several small RCTs failed to 
show any benefit of SDD over standard care following liver transplant. 
9. Conclusion and recommendations 
The evidence so far shows a decrease in 28 day mortality and reduction in bacteraemia in 
high risk patients and suggests that SDD should be regularly used in ICU settings. However 
SDD is still not common practice in most ICUs as many intensivists still question its safety 
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and efficacy. In a UK based survey of ICUs to document the use of SDD [106], 95% of British 
centres did not use SDD, mainly because of concerns regarding resistance. In addition there 
is a reluctance to use intravenous antibiotics in many of those who used SDD in intubated 
patients. Convincing the medical world of the effectiveness and safety of SDD will require 
more robust data about antibiotic resistance with SDD and SOD. 
9.1. Clostridium difficile infection 
Clostridium difficile is an anaerobic, spore-forming, gram-positive rod found in the intestines 
of 2-5% of the healthy human population [115] but responsible for 16-25% of hospital-
acquired antibiotic-associated diarrhoea.[116] It has been recognised as an important cause 
of antibiotic-associated colitis since the introduction of clindamycin in 1977 when it was 
understood that the disturbance of bowel flora by antimicrobial agents allowed overgrowth 
and subsequent infection by Clostridium difficile.[117] Transmission occurs through the feco-
oral route via contact with contaminated surfaces, with the hands of healthcare workers 
being potential routes of contamination. Vegetative bacterial cells produce spores in 
conditions of stress, making them resistant to commonly used techniques of surface 
disinfection such as alcohol handrubs, most disinfectants and antibiotics. It is however 
susceptible to chlorine-based antiseptics such as diluted bleach.[118] The spectrum of 
disease is wide and ranges from asymptomatic carriage to fulminant pseudomembraneous 
colitis which may be fatal.  
Toxin synthesis by C. difficile mediates disease progression and the severity of illness. The 
potent exotoxins produced by C. difficile have been labelled A and B. They are both large 
monoglycosyltransferases that catalyse the glucosylation and inactivation of Rho-GTPases, 
the small regulatory proteins of the actin cell cytoskeleton, leading to disruption of the cell 
cytoskeleton and subsequent cell death. Some strains of C.difficile produce an unrelated 
binary toxin which consists of two separate components: CDTa and CDTb. CDTb mediates 
translocation of CDTa into cells which allows the disruption of cytoskeleton proteins 
through phosphorylation, ultimately causing cell death.[118] The virulence of different 
strains of C. difficile is related to the rate of toxin production. Hypervirulent strains such as 
the molecular type NAP1/027/BI, have been found to have more robust toxin production 
and show an earlier spore-formation than other strains thus causing more severe 
infections.[119] Excessive toxin production in this strain has been traced to a mutation in the 
Toxin B encoding gene sequence.[120] Another emerging strain is the PCR ribotype 078, 
which is associated with community-associated C.difficile infection and has been isolated in 
animal and food products.[121]  
9.2. Epidemiology 
The emergence of C. difficile-associated disease (CDAD) can be traced back to the start of the 
antibiotic era. Antibiotic-associated diarrhoea and colitis became well established and C. 
difficile was identified as the cause of most of these cases in 1978. The earliest cases were 
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attributed to clindamycin but later, as the use of cephalosporins and wide spectrum 
penicllins increased, these antibiotics were increasingly implicated as causes of CDAD. An 
important outbreak in the US between 1989 and 1992 was traced to a strain of C. difficile with 
resistance to clindamycin.[122] Since 2003, an increase in the incidence of CDAD was 
observed, along with a decrease in their response to the standard antibiotic regimens. The 
hypervirulent strain NAP1/027/BI was identified as a cause of several outbreaks in North 
America and Europe and is believed to be related to the increase in use of fluoroquinolones, 
to which this strain is particularly resistant.[123,124]  
9.3. Risk factors for CDAD 
Antibiotic use is the strongest factor associated with CDAD. The most important mechanism 
involves the disruption of normal colonic commensal bacterial populations providing a 
niche for C. difficile to multiply and produce toxins. Resistance to antibiotics plays an 
important role in infections due to strains with increased virulence such as the NAP1/027/B1 
strain.[125] Antibiotics commonly implicated include fluoroquinolones, clindamycin, broad-
spectrum penicillins and cephalosporins. However, all antibiotics (including metronidazole 
and vancomycin) can predispose to C.difficile infection by disrupting the anaerobic gut flora. 
In fact it is hypothesised that the same antibiotics used for treating CDAD might be 
responsible for the recurrence of CDAD after treatment.[126] It has been shown that both the 
use of broad-spectrum antibiotics and prolonged courses of antimicrobials increase the risk 
of CDAD.[127,128] Advanced age is also an important risk factor associated with CDAD 
prevalence and severity. The increased frequency of comorbidities places elderly patients at 
higher risk of mortality and serious infections though compromised immune function also 
plays an important role.[126] The role of gastric acid suppression with proton pump 
inhibitors has also been implicated in the pathogenesis of CDAD though the evidence is 
equivocal.  
9.4. Diagnosis and investigations  
In most cases of suspected CDAD, the clinical presentation and microbiological evidence of 
toxin-producing C. difficile in stools is sufficient for diagnosis. The clinical picture may 
include bloody diarrhoea with abdominal pain and tenderness and ileus with abdominal 
pain, vomiting and reduced bowel motility. Pseudomembraneous colitis can be diagnosed 
by the visualisation of pseudomembranes at endoscopy while toxic megacolon presents 
with characteristic radiologic findings.[129] The markers of disease severity are outlined in 
Table 3. Microbiological evidence of infection is obtained from stool culture or assay for 
stool C. difficile toxin (CDT). Different tests can be used to detect the toxins. The most widely 
used test is the enzyme immunoassay (EIA) for toxin A, toxin B or both. The EIA CDT assay 
has sensitivities and specificities of 50-90% and 70-95%, respectively. Diagnostically, 
C.difficile cell culture cytotoxin assay remains the gold standard with sensitivity and 
specificity of 93% and 89%.[130]  
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Physical findings Blood investigations Imaging studies 
Fever, rigors, haemodynamic 
instability (including 
vasodilatory or septic shock), 
signs of peritonitis, (including 
decreased bowel sounds, 
abdominal tenderness, 
rebound tenderness and 
guarding), signs of ileus 
(including vomiting and 
absent passage of stool). 
Admixture of blood with 
stools is rare in CDI and the 
correlation with severity of 
disease is uncertain 
marked leukocytosis 
(leukocyte count > 15 X 109/L)
marked left shift (band 
neutrophils >20% of 
leukocytes) 
rise in serum creatinine (>50% 
above the baseline) 
elevated serum lactate 
distension of large intestine 
colonic wall thickening 
including low-attenuation 
mural thickening 
pericolonic fat stranding 
ascites not explained by other 
causes 
The correlation of haustral or 
mucosal thickening, 
including thumbprinting, 
pseudopolyps and plaques 
with severity of disease is 
unclear. 
 
Table 3. Markers of severe disease [127] 
9.5. Treatment 
The management of CDAD is tailored to the severity of the condition. The treatment 
recommended by the ESCMID guidelines (2009) [129] is summarised in Table 4.  
 
Degree of severity
Mild (stool frequency 
<4 times daily, no 
signs of colitis) 
Moderate (no markers 
of severe disease) 




Stop antibiotics and 
observe closely 
Metronidazole 500 
mg tds orally for 10 
days  
Vancomycin 125 mg qds 





mg tds intravenously 
for 10 days (A-III) 
Metronidazole 500 mg 
tds intravenously for 10 
days (A-III) + intracolonic 
vancomycin 500 mg in 
100 mL of normal saline 
every 4–12 h (C-III) 
and/or vancomycin 500 
mg qds by nasogastric 
tube (C-III) 
Table 4. Treatment of C.difficile infection [129] 
Oral vancomycin may be replaced by teicoplanin 100mg twice daily. Other antibiotics have 
been shown to be effective in CDAD but are not as yet recommended for routine use. In a 
phase 3 clinical trial [131], fidaxomycin had a better response rate and a lower recurrence 
rate than standard dose vancomycin. Oral rifaximin was studied on comparatively smaller 
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numbers. Neff et al [132] report three liver transplant patients with moderately severe 
CDAD who had relapsed after treatment with metronidazole and did not tolerate 
vancomycin. All three showed a good response after 28 days of rifaximin 400mg three times 
daily. In another small study [133], there was only one recurrence after treatment of 8 
patients with rifaximin for ten days. If severe disease does not respond to medical therapy, 
surgical intervention may be necessary. Indications for colectomy include perforation of the 
colon and systemic inflammation with deteriorating clinical condition not responding to 
antibiotic therapy. This includes the clinical diagnoses of toxic megacolon and severe ileus. 
Colectomy should preferably be performed before colitis is very severe. Serum lactate may 
serve as a marker of severity with surgery ideally performed before lactate exceeds 
5.0mmol/L.[127]  
9.6. Recurrence and the role of fecal transplant 
Recurrence of infection is defined as the recurrence of symptoms due to incomplete 
clearance of the initial infection. 15-30% of patients with CDAD experience recurrent 
infections in spite of seemingly adequate treatment.[134] Various combinations of antibiotics 
(Table 5) have been suggested for the management of recurrent infections as well as 
measures to normalise the intestinal flora using probiotics or fecal transplantation. Healthy 
donor fecal installation has been proposed as a way to restore normal bowel flora in patients 
with CDAD recurrence not responding to antibiotics. Several studies have been performed 
to date with most showing favourable results [135] but the lack of well designed RCTs 
makes the evidence weak and more studies are needed before it can be formally 
recommended in the guidelines. 
 
First recurrence Second recurrence Third recurrence 
Mild to moderate 
infection - 
Metronidazole at a 
dose of 500 mg orally 
three times daily for 
10 to 14 days 
Severe infection or 
unresponsive to or 
intolerant of 
metronidazole - 
Vancomycin at a dose 
of 125 mg orally four 
times daily for 10 to 
14 days 
Prolonged vancomycin orally 
in tapered and pulsed doses, 
for example: 
125 mg four times daily for 14 
days 
125 mg twice daily for seven 
days 
125 mg once daily for seven 
days 
125 mg once every two days 
for eight days (four doses) 
125 mg once every three days 
for 15 days (five doses) 
Vancomycin at a dose of 125 mg 
orally four times daily for 14 days, 
combined with any of the other 
options for recurrent infection (not 
evidence based): 
Intravenous immunoglobulin at a 
dose of 400 mg per kg body weight 
once every three weeks, for a total of 
two or three doses depending on 
effect. 
Vancomycin, followed by rifampicin 
at a dose of 400 mg twice daily for 14 
days 
Healthy donor fecal implantation 
Table 5. Management of CDAD recurrence [134] 
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10. Conclusion 
International guidelines [136] have issued a list of evidence-based infection control measures 
intended to contain outbreaks of CDI within hospitals. Measures include the strict use of 
hand hygiene using soap and water, the use of gloves and gowns when approaching an 
infected patient, isolation of infected patients in single rooms and maintaining contact 
precautions for the duration of diarrhoea. Routine identification and treatment of carriers is 
not recommended. Identification of potential sources of infection, such as rectal 
thermometers, can help reduce the incidence of CDAD. Frequent use of chlorine-containing 
cleaning agents to disinfect the clinical area along with routine environmental screening for 
C.difficile are also recommended. Restricting the use of cephalosporins and clindamycin may 
also be useful. The frequency, duration of antibiotic courses and number of agents used 
should be as recommended by international guidelines. Implementing these 
recommendations was shown to be of benefit by the Centre for Disease Control and 
Prevention [137] in several hospitals in the USA with a decline in C. difficile infection (CDI) 
rate of 20% among 71 hospitals participating in the CDI prevention program, thus 
confirming that with C. difficile infections, prevention is better than cure. 
10.1. Probiotics 
The term probiotic, first introduced in 1965 by Lilly and Stillwell, describes bacterially-
derived factors that stimulate the growth of other organisms. This definition was updated 
by Fuller in 1989 who defined probiotics as viable organisms with a beneficial effect on the 
host. Fermented ingredients containing no viable organisms but that still cause beneficial 
changes in the intestinal flora are termed prebiotics, while symbiotics are mixtures of pre- and 
probiotics. Lactobacillus, Bifidobacterium, Eschericia coli, Saccharomyces cerevisae and Bacillus 
species are the microflora most commonly used in probiotics.[138] The healthy human gut 
hosts a large community of microorganisms that interact with the host in a positive manner. 
Disruption of the normal gut flora by antibiotics or infections causes a change in bowel 
function, most frequently resulting in diarrhoea. It has been proposed that the normal 
commensal flora occupies most binding sites on the intestinal mucosa and out-competes 
potentially pathogenic organisms, thus providing a protective effect on the host. Probiotics 
are believed to function in a similar way to the normal commensal flora by colonising the 
intestinal contents so as to prevent the proliferation of potentially pathogenic organisms by 
competing for resources and intestinal binding sites. Probiotics may also lead to an 
improvement in intestinal barrier function, modulation of the immune system by induction 
of protective cytokines and modulation of pain perception. 
Probiotics have been around for decades and are available in different formulations 
including capsules, powders and fermented milk products. However, evidence of their 
benefit has been relatively scarce until recently as most studies were hampered by poor 
standardisation in view of the different species and strains used. Species used vary widely 
as do the number of viable organisms and their resistance to gastric acid. Some examples of 
commercially available probiotics are: Erceflora (Bacillus clausii), Align® (B. infantis), 
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Bioflor® (Saccharomyces boulardii), Culturelle® (L. rhamnosus GG), DanActive® (L. casei), 
Mutaflor® (E. coli Nissle 1917), Florastor® (Saccharomyces boulardii), and VSL#3® 
(Bifidobacterium breve, B. longum, B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, 
L. bulgaricus, Streptococcus thermophilus). The evidence on the use of probiotics in 
inflammatory bowel disease and pouchitis has been described earlier. 
10.2. Infectious diarrhoea 
Infectious diarrhoea is a major cause of morbidity and mortality especially in third world 
countries. Most studies with probiotics analysing the effect on diarrhoea duration have been 
in paediatric patients and they show a significant benefit. In a meta-analysis [139] of 63 
studies of which 56 involved infants and young children, there was a significant decrease in 
the mean duration of diarrhoea (mean difference 24.76 hours; n=4555, trials=35), diarrhoea 
lasting ≥4 days (risk ratio 0.41; n=2853, trials=29) and stool frequency on day 2 (mean 
difference 0.80; n=2751, trials=20). However, there was a wide variation in the probiotics 
used, patient characteristics and clinical settings. When probiotics are used in conjunction 
with rehydration therapy they appear to be safe and have clear benefits in shortening the 
duration of diarrhoea and reducing stool frequency in acute infectious diarrhoea.  
4 randomised controlled trials (n=464) comparing specified probiotic agents with placebo or 
no treatment in children with persistent diarrhoea (diarrhoea lasting more than 14 days) 
[140] showed that probiotics reduced the duration of persistent diarrhoea by a mean of 4.2 
days and significantly reduced stool frequency at day 5. In a randomised controlled trial 
that randomised 88 children younger than two years old with acute diarrhoea to receive 
S.boulardii or placebo there was an average reduction in the duration of diarrhoea of 1.44 
days in the treatment arm along with a significant reduction in stool frequency at day 4.[141] 
The dose-dependent effect of administering L. rhamnosus on fecal shedding of rotavirus was 
analysed in another study. 23 children with acute rotavirus infection were randomised to 
placebo, low-dose or high-dose L rhamnosus.[142] This trial showed no significant reduction 
in viral shedding in the low dose group but a significant reduction in the high dose group 
suggesting that a minimum of 6 x 108 CFU (colony forming units) for 3 days has to be given 
to paediatric patients to achieve a good effect. Other studies [143] also suggest a definite but 
modest benefit in probiotic use in acute infectious diarrhoea, especially in rotavirus-induced 
diarrhoea.  
10.3. Antibiotic-associated diarrhoea and Clostridium difficile-associated disease 
Antibiotic-associated diarrhoea (AAD) occurs in about 25% of patients receiving antibiotics, 
with rates varying between different populations and according to the type of antibiotic 
used.[144] Clostridium difficile accounts for only 10-20% of cases and a causative agent is 
frequently not found. Diarrhoea may begin following a single dose of antibiotic or up to 6 
weeks after treatment [145] and can range in severity from mild symptoms to the life-
threatening colitis usually associated with C. difficile. Risk factors for AAD include oral 
broad-spectrum antibiotics, advanced age and prolonged hospital stay. Probiotics have been 
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advocated to reduce the incidence of AAD since they help re-establish beneficial intestinal 
flora after disturbance by antibiotics. Probiotic organisms that have been studied for 
preventing AAD include Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus 
GG and Saccharomyces boulardii. 
Several meta-analysis have highlighted the positive effects of probiotics on AAD. In [146], 8 
RCTs (n=1220) evaluating the effectiveness of probiotics in preventing AAD and CDAD 
were analysed. Probiotics used included S. boulardii in 3 studies and various strains of 
Lactobacillus, Bifidobacterium bifidum and Streptococcus thermophilus in different combinations 
in the other 5 studies. Results were found to be protective for AAD (Risk Ratio [RR]: 0.56; 
95% CI, 0.44–0.71) as well as for CDAD (RR: 0.29; 95% CI 0.18–0.46). In [147], different 
strains of Lactobacillus as single agents in the prevention of AAD were analysed in 10 RCTs 
(n=1862). The total daily dose of Lactobacillus ranged from 2 x 109 to 4 x 1010 CFUs and was 
administered throughout the entire antibiotic treatment (5-14 days) for all patients. The 
combined RR of developing AAD was significantly lower with Lactobacillus when compared 
with placebo (RR 0.35, 95% CI 0.19-0.67). In a subgroup analysis, this benefit was seen 
among adult but not among pediatric patients (RR 0.24, 95% CI 0.08-0.75 and RR 0.44, 95% 
CI 0.18-1.08, respectively). Considerable evidence backs the use of probiotic agents 
(especially Lactobacillus species and S. boulardii) as an extra measure to prevent AAD and 
CDAD.  
10.4. Probiotics in IBD 
Probiotics alter the microbial concentrations of the intestines and may also be used to 
deliver microbial metabolic products which affect intestinal mucosal inflammation in IBD. 
There is little evidence of benefit with currently available probiotics in CD though newer 
probiotics composed of other micro-organisms may prove beneficial in the future. On the 
other hand, studies have shown a benefit of probiotics in recurrent and relapsing antibiotic 
sensitive pouchitis and in mild UC. In fact, recent practice guidelines [148] on the 
management of pouchitis suggest that in patients with prompt recurrence of pouchitis 
following antibiotic cessation, and in those with multiple recurrences of pouchitis despite 
antibiotics, either VSL#3TM or chronic use of antibiotics may be helpful. These guidelines 
however do not recommend probiotics in the acute treatment of pouchitis.[148] 
Probiotics may prevent relapse in chronic pouchitis and ulcerative colitis, and may also 
prevent the development of pouchitis postoperatively. However, further studies are needed 
to identify optimal dosing, duration of therapy, delivery methods and whether blends of 
different strains of probiotics are superior to single strains.[149] Following a systematic 
review of studies using VSL#3TM, E.coli Nissle 1917 and YakultTM, Mallon et al concluded 
that the addition of probiotics to conventional medical therapy had no effect in overall 
remission rate in mild to moderate UC.[150-152] Other randomized controlled trials have 
also shown conflicting results with some showing a higher rate of remission (with VSL#3 or 
a combination of a prebiotic and B.longum) [153-155] and others showing little or no benefit 
(with E.coli Nissle 1917).[156] There are no recommendations regarding the use of probiotics 
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as maintenance therapy in UC. Few studies have been carried out using single or combined 
strain probiotics as maintenance therapy in UC with 3 of 4 single probiotic trials using E.coli 
strain Nissle 1917. The results from these reports showed that probiotics had similar efficacy 
to 5-aminosalicylates.[153,157-159] In children with active distal ulcerative colitis, decreased 
mucosal inflammation was noticed following rectal infusion of Lactobacillus reuteri.[160] 
Even non-living probiotic bacteria may prevent the onset of severe intestinal inflammation 
by strengthening the integrity of the intestinal barrier and stabilising the environment for 
gut microbiota.[161,162] 
The risks of probiotic use are generally low, but cases of fungaemia in ICU patients on S. 
boulardii and a case of sepsis from a Lactobacillus strain in a UC patient have been 
reported.[163,164] An important consideration before starting probiotics is whether the 
patient is on immunosuppressing agents. There is no evidence for the use of probiotics in 
severe IBD and little clinical evidence on the safety of probiotics in severely 
immunocompromised IBD patients. 
10.5. Mortality of preterm infants with necrotising enterocolitis 
Necrotising Enterocolitis (NEC) is an important cause of morbidity and mortality in preterm 
and very low birth weight (<1500g) infants. There is strong evidence [165-167] that the 
administration of enteral probiotics plays an important role in establishing benign 
commensal flora and preventing NEC and its complications. In these studies, the most 
commonly used species were Bifidobacterium and Lactobacillus species.[168] Very few adverse 
events from probiotics have been reported and they are thus being recommended as 
evidence-based treatment.[169]  
10.6. Irritable Bowel Syndrome 
Irritable Bowel Syndrome (IBS) is a heterogeneous group of disorders characterised by 
functional bowel symptoms such as abdominal pain, bloating and changes in bowel habit in 
the absence of other pathologies which might explain these symptoms. IBS is typically 
difficult to treat as its aetiology is still poorly understood. Targeting the intestinal flora with 
probiotics has been an attractive potential treatment and has shown some promise in several 
meta-analyses.[170-174] These studies showed a modest improvement in the patients’ 
symptoms when using strains like S. boulardii and Lactobacillus rhamnosus GG. Longer term 
studies with specific strains are warranted to clarify the most appropriate species and long-
term effects with probiotics. 
11. Conclusion 
The emergence of probiotics as a popular type of alternative medicine has preceded by 
several decades their promotion as an evidence-based treatment. Their role in treatment or 
prevention for several important conditions namely NEC, UC, pouchitis and AAD is 
expected to fuel further research as many unanswered questions still remain. In spite of 
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many large trials the data is still relatively weak to allow specific recommendations on 
which probiotics to prescribe in specific conditions. Optimum dose recommendations also 
remain to be clarified.  
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